Header Logo

Connection

Kathleen Moore to Polyethylene Glycols

This is a "connection" page, showing publications Kathleen Moore has written about Polyethylene Glycols.
Connection Strength

0.101
  1. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
    View in: PubMed
    Score: 0.039
  2. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290.
    View in: PubMed
    Score: 0.033
  3. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):204-9.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.